No Data
No Data
The 8.2% Return This Week Takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) Shareholders Five-year Gains to 194%
Express News | BioCryst Pharmaceuticals Inc - Increases Wholesale Acquisition Cost for Orladeyo to $44,484.33 per 28-Day Pack
BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference
KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says
KalVista Wins New Buy at BofA on Potential of Lead Candidate
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Institutional Investors Lost 5.5% Last Week but Have Benefitted From Longer-term Gains
No Data